Berbamine

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

小檗胺及其衍生物是通过靶向 CAMKII 抑制肝癌生长的有前途的化合物。

Berbamine has high binding affinity toward the (GGA);G-quadruplex. Berbamine and its derivatives are promising agents to suppress liver cancer growth by targeting CAMKII. Berbamine may be the first ATP-competitive inhibitor of CaMKII γ, could be as a new type of molecular targeted agent through inhibition of the CaMKII γ activity for treatment of leukemia. 4. Berbamine can enhance the antitumor activity of gemcitabine by inhibiting cell growth and inducing apoptosis, possibly through the regulation of the expression of apoptosis-related proteins and the activation of TGF-β/Smad signaling pathway. Berbamine confers cardioprotection against I/R injury by attenuating [Ca(2+)inf(i) overloading and preventing calpain activation through the activation of the PI3K-Akt-GSK3β pathway and, subsequently, opening of the mitoK(ATP) channel.

Cell Viability Assay Cell Line:KM3 cell Concentration:1?32 μg/mL Incubation Time:24, 48, or 72 h Result:Inhibited the growth of KM3 cells in a dose- and time-dependent manner.Apoptosis Analysis Cell Line:KM3 cell Concentration:4 μg/mLIncubation Time:6, 12, or 24 h Result:Induced apoptosis in a time-dependent manner treated at 8 μg/mL.Western Blot Analysis Cell Line:KM3 cell Concentration:8 μg/mL Incubation Time:0, 6, 12, or 24 h Result:Inhibited p65 nuclear translocation and expression of IKKα.

Animal Model:Huh7 xenograft NOD/SCID mice modelDosage:100mg/kg Administration:Oral gavage (p.o.), twice a day for 5 consecutive days Result:Suppressed tumor growth and reduced tumor weight by 70%.

——

Membrane Transporter/Ion Channel

TRP/TRPV Channel

CAMKIIγ

Cancer

——

478-61-5

608.73

C37H40N2O6

>98% (HPLC)

In Vitro:?DMSO : 100 mg/mL (164.28 mM)

CN1CCC2=CC(=C3C=C2C1CC4=CC=C(C=C4)OC5=C(C=CC(=C5)CC6C7=C(O3)C(=C(C=C7CCN6C)OC)OC)O)OC

——

(-20℃)

With Ice Pack

≥ 2 years